Search Results
ENETS Center of Excellence, Department of Endocrinology, University Hospital Basel, Basel, Switzerland
Department of Clinical Research, University of Basel, Basel, Switzerland
Search for other papers by Julie Refardt in
Google Scholar
PubMed
Search for other papers by Wouter T Zandee in
Google Scholar
PubMed
Search for other papers by Tessa Brabander in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Gaston J H Franssen in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Department of Clinical Research, University of Basel, Basel, Switzerland
Search for other papers by Emanuel Christ in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Johannes Hofland in
Google Scholar
PubMed
surface, with the somatostatin receptor subtype 2 (SST2) being expressed in up to 90% of gastroenteropancreatic NETs ( Reubi et al. 2010 , Gatto & Hofland 2011 ). According to this feature, SSTR-based imaging is the current standard for diagnosing and
Search for other papers by Margaux Foulfoin in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, Lyon, France
Search for other papers by Emmanuelle Graillot in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de chirurgie, Lyon, France
Search for other papers by Mustapha Adham in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de radiologie, Lyon, France
Search for other papers by Pascal Rousset in
Google Scholar
PubMed
Search for other papers by Julien Forestier in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service Central d’Anatomie et Cytologie Pathologiques, Lyon, France
Search for other papers by Valérie Hervieu in
Google Scholar
PubMed
Search for other papers by Philip Robinson in
Google Scholar
PubMed
Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, Lyon, France
Search for other papers by Thomas Walter in
Google Scholar
PubMed
neuroendocrine tumors . New England Journal of Medicine 371 224 – 233 . ( doi:10.1056/NEJMoa1316158 ) Coriat R Walter T Terris B Couvelard A Ruszniewski P 2016 Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors
Search for other papers by Annemiek Walenkamp in
Google Scholar
PubMed
Search for other papers by Guillermo Crespo in
Google Scholar
PubMed
Search for other papers by Felipe Fierro Maya in
Google Scholar
PubMed
Search for other papers by Reidar Fossmark in
Google Scholar
PubMed
Search for other papers by Peter Igaz in
Google Scholar
PubMed
Search for other papers by Anja Rinke in
Google Scholar
PubMed
Search for other papers by Gianluca Tamagno in
Google Scholar
PubMed
Department of Medical Oncology, Department of Medical Oncology, Department of Endocrine Oncology, Department of Cancer Research and Molecular Medicine, 2nd Department of Medicine, Department of Gastroenterology, Department of General Internal Medicine, Department of Clinical Sciences and Community Health (DISCCO), Laboratory of Endocrine and Metabolic Research, Department of Endocrine Oncology, UCL Cancer Institute, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
Search for other papers by Giovanni Vitale in
Google Scholar
PubMed
Search for other papers by Kjell Öberg in
Google Scholar
PubMed
Search for other papers by Tim Meyer in
Google Scholar
PubMed
in metastatic gastroenteropancreatic neuroendocrine tumours . British Journal of Cancer 109 1414 – 1419 . ( doi:10.1038/bjc.2013.470 ). Ameri P Ferone D 2012 Diffuse endocrine system, neuroendocrine tumors and immunity: what's new
Search for other papers by Louis de Mestier in
Google Scholar
PubMed
Search for other papers by Angela Lamarca in
Google Scholar
PubMed
Search for other papers by Jorge Hernando in
Google Scholar
PubMed
Division of Endocrinology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Search for other papers by Wouter Zandee in
Google Scholar
PubMed
Search for other papers by Teresa Alonso-Gordoa in
Google Scholar
PubMed
Search for other papers by Marine Perrier in
Google Scholar
PubMed
Search for other papers by Annemiek ME Walenkamp in
Google Scholar
PubMed
Search for other papers by Bipasha Chakrabarty in
Google Scholar
PubMed
Search for other papers by Stefania Landolfi in
Google Scholar
PubMed
Search for other papers by Marie-Louise F Van Velthuysen in
Google Scholar
PubMed
Search for other papers by Gursah Kats-Ugurlu in
Google Scholar
PubMed
Search for other papers by Alejandra Caminoa in
Google Scholar
PubMed
Search for other papers by Maxime Ronot in
Google Scholar
PubMed
Search for other papers by Prakash Manoharan in
Google Scholar
PubMed
Search for other papers by Alejandro Garcia-Alvarez in
Google Scholar
PubMed
Search for other papers by Tessa Brabander in
Google Scholar
PubMed
Search for other papers by María Isabel García Gómez-Muriel in
Google Scholar
PubMed
Search for other papers by Guillaume Cadiot in
Google Scholar
PubMed
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Jaume Capdevila in
Google Scholar
PubMed
Search for other papers by Marianne E Pavel in
Google Scholar
PubMed
Search for other papers by Jérôme Cros in
Google Scholar
PubMed
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study . Endocrine-Related Cancer 26 227 – 239 . ( https://doi.org/10.1530/ERC-18-0424 ) Cives M Ghayouri M Morse B Brelsford M Black M Rizzo A
Search for other papers by L D de Hosson in
Google Scholar
PubMed
Search for other papers by J Stelwagen in
Google Scholar
PubMed
Search for other papers by G Bouma in
Google Scholar
PubMed
Search for other papers by B Sijtema in
Google Scholar
PubMed
Search for other papers by S Huitema in
Google Scholar
PubMed
Search for other papers by H J R van Faassen in
Google Scholar
PubMed
Search for other papers by G H de Bock in
Google Scholar
PubMed
Search for other papers by D J A de Groot in
Google Scholar
PubMed
Search for other papers by M J E Campmans-Kuijpers in
Google Scholar
PubMed
Search for other papers by I P Kema in
Google Scholar
PubMed
Search for other papers by E G E de Vries in
Google Scholar
PubMed
Search for other papers by A M E Walenkamp in
Google Scholar
PubMed
in 138 gastroenteropancreatic NET patients ( Massironi et al . 2017 ). NET patients experience a lower quality of life (QoL) as compared with the general population, among others, due to increased bowel movements ( Pearman et al . 2016
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
Search for other papers by Stavroula Antoniou in
Google Scholar
PubMed
Search for other papers by George Kanakis in
Google Scholar
PubMed
Search for other papers by Nikolaos Economopoulos in
Google Scholar
PubMed
Search for other papers by Dimitra Rontogianni in
Google Scholar
PubMed
Search for other papers by Anastasios Ntavatzikos in
Google Scholar
PubMed
Search for other papers by Nikolaos Tsavaris in
Google Scholar
PubMed
Search for other papers by Dimitrios Pectasides in
Google Scholar
PubMed
Search for other papers by George Dimitriadis in
Google Scholar
PubMed
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Downstaging of gastroenteropancreatic tumours (arrows) after TeBeSa combination therapy. MRI details shown before treatment (a) and (c) and after six cycles (b) and (d) for two patients with a pancreatic (a)/(b) and a duodenal tumour (c)/(d). During the past 4
University of Alabama at Birmingham, Department of Surgery, Division of Surgical Oncology, Birmingham, Alabama, USA
Search for other papers by Sarah B Bateni in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical evaluative sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
Search for other papers by Natalie G Coburn in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Search for other papers by Calvin Law in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical evaluative sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
Search for other papers by Simron Singh in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical evaluative sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
Search for other papers by Sten Myrehaug in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical evaluative sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
Search for other papers by Angela Assal in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical evaluative sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
Search for other papers by Julie Hallet in
Google Scholar
PubMed
.4160 ) Massironi S Campana D Pusceddu S Albertelli M Faggiano A Panzuto F Smiroldo V Andreasi V Rossi RE Maggio I , 2020 Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: data from a
Search for other papers by M Cives in
Google Scholar
PubMed
Search for other papers by P L Kunz in
Google Scholar
PubMed
Search for other papers by B Morse in
Google Scholar
PubMed
Search for other papers by D Coppola in
Google Scholar
PubMed
Search for other papers by M J Schell in
Google Scholar
PubMed
Search for other papers by T Campos in
Google Scholar
PubMed
Search for other papers by P T Nguyen in
Google Scholar
PubMed
Search for other papers by P Nandoskar in
Google Scholar
PubMed
Search for other papers by V Khandelwal in
Google Scholar
PubMed
Search for other papers by J R Strosberg in
Google Scholar
PubMed
improvement in time-to-progression, thus defining a new paradigm in the treatment of small-intestinal NETs ( Rinke et al . 2009 ). More recently, the CLARINET trial randomized patients with hormonally nonfunctioning gastroenteropancreatic NETs to receive
Search for other papers by Cecilia Piani in
Google Scholar
PubMed
Search for other papers by Giulia M Franchi in
Google Scholar
PubMed
Search for other papers by Chiara Cappelletti in
Google Scholar
PubMed
Search for other papers by Marina Scavini in
Google Scholar
PubMed
Search for other papers by Luca Albarello in
Google Scholar
PubMed
Search for other papers by Alessandro Zerbi in
Google Scholar
PubMed
Search for other papers by Paolo Giorgio Arcidiacono in
Google Scholar
PubMed
Search for other papers by Emanuele Bosi in
Google Scholar
PubMed
Search for other papers by Marco F Manzoni in
Google Scholar
PubMed
the last few decades may be accounted for by increased awareness, improved diagnostic tools and a revision in the definition. The main primary sites of NETs are the gastro–entero–pancreatic (GEP) tract (62–67%) and the lung (22–27%; Taal & Visser 2004
Search for other papers by Paula Fontes Asprino in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, São Paulo, Brazil
Search for other papers by Rudinei Diogo Marques Linck in
Google Scholar
PubMed
Search for other papers by Jônatas Cesar in
Google Scholar
PubMed
Search for other papers by Florêncio Porto Freitas in
Google Scholar
PubMed
Search for other papers by Fernanda Christtanini Koyama in
Google Scholar
PubMed
Search for other papers by Rachel Simões Pimenta Riechelmann in
Google Scholar
PubMed
Search for other papers by Frederico Perego Costa in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, São Paulo, Brazil
Search for other papers by Paulo Marcelo Gehm Hoff in
Google Scholar
PubMed
Search for other papers by Pedro Alexandre Favoretto Galante in
Google Scholar
PubMed
Search for other papers by Diogo Meyer in
Google Scholar
PubMed
Search for other papers by Anamaria Aranha Camargo in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, São Paulo, Brazil
Search for other papers by Jorge Sabbaga in
Google Scholar
PubMed
, epidemiological studies have demonstrated that non-syndromic individuals with an affected relative are at an increased risk of developing gastroenteropancreatic (GEP) NENs. In individuals with affected siblings, the relative risk of GEP NEN increases by 13.4-fold